Understanding cardiovascular risk in rheumatoid arthritis: Still a long way to go

Atherosclerosis

Volumn 256, Issue , 2017, Pages 123-124

  Gualtierotti, Roberta ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular risk; IL 6 blockade; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; TOCILIZUMAB; BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6 RECEPTOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN T;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ACTIVITY; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR DISEASE; RISK FACTOR;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-6; RISK FACTORS; TROPONIN T;

EID: 85008211294     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.11.009     Document Type: Editorial

References (22)

1. [1] Gabriel, S.E., Epidemiology of the rheumatic diseases. Harris, E.D., Ruddy, S., Sledge, C.B., (eds.) Kelley's Textbook of Rheumatology, 6th, 2000, W B Saunders Company, Philadelphia, 321–333.
2. [2] McInnes, I.B., Schett, G., The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365:23 (2011), 2205–2219.
3. [3] Nurmohamed, M.T., Heslinga, M., Kitas, G.D., Cardiovascular comorbidity in rheumatic diseases. Nat. Rev. Rheumatol. 11:12 (2015), 693–704.
4. [4] Welsh, P., Tuckwell, K., McInnes, I.B., Sattar, N., Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis 254 (2016), 167–171.
5. [5] Lindhardsen, J., Ahlehoff, O., Gislason, G.H., Madsen, O.R., Olesen, J.B., Torp-Pedersen, C., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 70:6 (2011), 929–934.
6. [6] Maradit-Kremers, H., Nicola, P.J., Crowson, C.S., Ballman, K.V., Gabriel, S.E., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 52:3 (2005), 722–732.
7. [7] Libby, P., Ridker, P.M., Hansson, G.K., Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347 (2011), 317–325.
8. [8] The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379:9822 (2012), 1214–1224.
9. [9] Cugno, M., Ingegnoli, F., Gualtierotti, R., Fantini, F., Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr. Vasc. Pharmacol. 8:2 (2010), 285–292.
10. [10] van den Oever, I.A., Sattar, N., Nurmohamed, M.T., Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann. Rheum. Dis. 73:6 (2014), 954–957.
11. [11] Cambridge, G., Acharya, J., Cooper, J.A., Edwards, J.C., Humphries, S.E., Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 228:1 (2013), 243–246.
12. [12] Agca, R., Heslinga, S.C., Rollefstad, S., Heslinga, M., McInnes, I.B., Peters, M.J., Kvien, T.K., Dougados, M., Radner, H., Atzeni, F., Primdahl, J., Södergren, A., Wallberg Jonsson, S., van Rompay, J., Zabalan, C., Pedersen, T.R., Jacobsson, L., de Vlam, K., Gonzalez-Gay, M.A., Semb, A.G., Kitas, G.D., Smulders, Y.M., Szekanecz, Z., Sattar, N., Symmons, D.P., Nurmohamed, M.T., EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis., 2016 Oct 3 pii: annrheumdis-2016-209775 http://dx.doi.org/10.1136/annrheumdis-2016-209775 [Epub ahead of print] PubMed PMID: 27697765.
13. [13] Westlake, S.L., Colebatch, A.N., Baird, J., Kiely, P., Quinn, M., Choy, E., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatol. (Oxford) 49:2 (2010), 295–307.
14. [14] Bili, A., Tang, X., Pranesh, S., Bozaite, R., Morris, S.J., Antohe, J.L., et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 66:3 (2014), 355–363.
15. [15] Cugno, M., Cardiovascular events and survival in rheumatoid arthritis: effects of anti-tumor necrosis factor-alpha treatment. Transl. Res. 157:1 (2011), 6–9.
16. [16] Sebba, A., Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Health Syst. Pharm. 65:15 (2008), 1413–1418.
17. [17] Schiff, M.H., Kremer, J.M., Jahreis, A., Vernon, E., Isaacs, J.D., van Vollenhoven, R.F., Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther., 13(5), 2011, R141.
18. [18] McInnes, I.B., Thompson, L., Giles, J.T., Bathon, J.M., Salmon, J.E., Beaulieu, A.D., et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis. 74:4 (2015), 694–702.
19. [19] Gualtierotti, R., Ingegnoli, F., Griffini, S., Grovetti, E., Meroni, P.L., Cugno, M., Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. Clin. Exp. Rheumatol. 34:3 (2016), 451–458.
20. [20] Makrilakis, K., Fragiadaki, K., Smith, J., Sfikakis, P.P., Kitas, G.D., Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin. Rheumatol. 34:3 (2015), 419–427.
21. [21] Kume, K., Amano, K., Yamada, S., Hatta, K., Ohta, H., Kuwaba, N., Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J. Rheumatol. 38:10 (2011), 2169–2171.
22. [22] Avouac, J., Meune, C., Chenevier-Gobeaux, C., Dieude, P., Borderie, D., Lefevre, G., et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J. Rheumatol. 41:2 (2014), 248–255.